Revenue Breakdown
Composition ()
No data
Revenue Streams
Aurinia Pharmaceuticals Inc (AUPH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Therapeutic Drug Division, accounting for 84.6% of total sales, equivalent to $1.35M. Other significant revenue streams include Diagnostic Division and Corporate. Understanding this composition is critical for investors evaluating how AUPH navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Aurinia Pharmaceuticals Inc maintains a gross margin of 88.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 43.10%, while the net margin is 273.35%. These profitability ratios, combined with a Return on Equity (ROE) of 59.91%, provide a clear picture of how effectively AUPH converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AUPH competes directly with industry leaders such as GLPG and RXRX. With a market capitalization of $1.89B, it holds a significant position in the sector. When comparing efficiency, AUPH's gross margin of 88.59% stands against GLPG's 99.95% and RXRX's 59.83%. Such benchmarking helps identify whether Aurinia Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
